ストックスクリーナーアプリを入手
11.96
3.82%
-0.57
Novocure Ltd (NVCR) 最新ニュース
NovoCure (NVCR) Stock Surges on Pancreatic Cancer Treatment Approval - Blockonomi
Novocure’s stock rises 37% on FDA clearance of pancreatic cancer treatment device - Yahoo Finance
Soleus Adds a Significant Number of Celcuity Shares - The Motley Fool
NovoCure (NVCR) Stock Soars Following Pancreatic Cancer Treatment Approval - CoinCentral
NovoCure (NVCR) stock is trending overnight — here's what you should know - MSN
NovoCure (NASDAQ:NVCR) Shares Gap UpTime to Buy? - MarketBeat
Assessing NovoCure (NVCR) Valuation After FDA Approval Of Optune Pax For Pancreatic Cancer - Yahoo Finance
Approval for pancreatic cancer treatment boosts NovocureGlobes - Globes - Israel Business News
HC Wainwright & Co. Raises NovoCure (NVCR) Price Target to $47 | - GuruFocus
NovoCure Stock Surges After FDA Approves Optune Pax - Benzinga
Novocure Wins FDA Nod for Optune Pax Pancreatic Cancer Treatment - Medical Product Outsourcing
Stock Market Today: Dow Jones, S&P 500 Futures Gain After Strong Jobs Report—Micron, Novocure, Fastly In Focus (UPDATED) - Benzinga
NovoCure stock price target raised to $47 from $39 at H.C. Wainwright By Investing.com - Investing.com India
NovoCure stock price target raised to $47 from $39 at H.C. Wainwright - Investing.com
NovoCure Limited's (NASDAQ:NVCR) 26% Dip In Price Shows Sentiment Is Matching Revenues - simplywall.st
Novocure (NVCR) Shares Surge on FDA Approval for Optune Pax - GuruFocus
U.S. Stock Futures Rise as Fastly and Novocure Surge - Intellectia AI
Novocure shares surge after FDA approves pancreatic cancer device By Investing.com - Investing.com South Africa
Novocure shares surge after FDA approves pancreatic cancer device - Investing.com India
Form 8-KMaterial Events - Stock Titan
First new pancreatic cancer treatment in nearly 30 years is wearable - Stock Titan
Novocure shares soar 30% after FDA nod for pancreatic cancer device - Investing.com Australia
FDA Approves Novocure's Optune Pax for Pancreatic Cancer Treatme - GuruFocus
NovoCure Ltd treatment gains FDA approval for pancreatic cancer - Traders Union
Novocure Ltd FDA Approval of Optune Pax for Pancreatic Cancer - TradingView
FDA clears Novocure (NVCR) Optune Pax for locally advanced pancreatic cancer - Stock Titan
NovoCure (NVCR) Stock Is Trending OvernightHere's What You Should Know - Bitget
Assessing NovoCure (NVCR) Valuation After Prolonged Share Price Weakness In Tumor Treating Fields Story - Sahm
HC Wainwright Has Bearish Forecast for NovoCure Q1 Earnings - Defense World
HC Wainwright Has Negative View of NovoCure FY2029 Earnings - MarketBeat
Novocure stock hits 52-week low at $10.66 By Investing.com - Investing.com South Africa
C WorldWide Group Holding A S Grows Position in NovoCure Limited $NVCR - MarketBeat
Novocure stock falls after CMS revokes billing privileges By Investing.com - Investing.com South Africa
Novocure stock falls after CMS revokes billing privileges - Investing.com
NovoCure (NASDAQ:NVCR) Sets New 52-Week LowWhat's Next? - MarketBeat
Novocure stock hits 52-week low at $10.66 - Investing.com
**NovoCure Faces CMS Billing Privileges Revocation** - TradingView
Take Profit: Is NovoCure Limited stock showing strong momentumTrade Volume Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Piper Sandler reiterates Overweight rating on NovoCure stock By Investing.com - Investing.com South Africa
Piper Sandler reiterates Overweight rating on NovoCure stock - Investing.com
Hussman Strategic Advisors Inc. Takes $1.09 Million Position in NovoCure Limited $NVCR - MarketBeat
NovoCure Limited (NVCR) Stock Analysis: An Investor’s Look at 81.53% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Emerald Mutual Fund Advisers Trust Has $248,000 Stock Position in NovoCure Limited $NVCR - MarketBeat
NovoCure Limited (NVCR): Investor Outlook on a 76% Potential Upside in Medical Device Innovation - DirectorsTalk Interviews
NovoCure Limited (NASDAQ:NVCR) Short Interest Update - MarketBeat
NovoCure Limited (NASDAQ:NVCR) Receives Average Rating of “Hold” from Analysts - Defense World
NovoCure’s (NVCR) “Neutral” Rating Reaffirmed at Wedbush - Defense World
Assessing NovoCure: Insights From 4 Financial Analysts - Benzinga
NovoCure (NVCR) Rating Reiterated as Neutral by Wedbush | NVCR S - GuruFocus
A Look At NovoCure (NVCR) Valuation After Record 2025 Revenue And CEO Transition - simplywall.st
NovoCure (NASDAQ:NVCR) Receives Neutral Rating from Wedbush - MarketBeat
HC Wainwright Has Bullish Estimate for NovoCure Q4 Earnings - MarketBeat
Leerink Partners Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $24 - Futubull
NovoCure Limited (NASDAQ:NVCR) Receives Average Rating of "Hold" from Analysts - MarketBeat
Brokers Set Expectations for NovoCure FY2030 Earnings - Defense World
0.88%
0.48%
大文字化:
|
ボリューム (24 時間):